30 closest matches · ranked by relevance
Von Hippel-Lindau Disease
Primary: Number of Patients With Pancreatic Lesions Defined by Simple Cysts, Microcystic Adenomas, Neuroendocrine Tumors & Other Solid Lesions of the Pancreas Who Had Significant…
Von Hippel-Lindau Syndrome
Primary: Overall Response Rate (Complete Response + Partial Response) — 13 Participants
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Von-Hippel Lindau · Kidney Disease, Chronic
Primary: Comparison in Radiologist's Lesion Evaluation: CEUS Versus B-mode Ultrasound — 0.13; 0.20 Dichotomized score
VHL Gene Mutation · VHL · VHL Syndrome
Primary: Overall Response Rate (ORR) in VHL Disease-Associated ccRCC Tumors — 0.0 Percentage of Participants
Renal Cancer · Von Hippel Lindau
Primary: Overall Response Rate. — 3; 0; 75; 0 percentage of participants
Pheochromocytoma · Paraganglioma
Primary: Number of Participants With Clinical Response (Partial Response + Complete Response) — 5; 0; 5; 2 Participants
HLRCC · Sporadic Papillary Renal Cell Cancer
Primary: Overall Response Rate — 72; 35 Percentage of participants
Hemangioma
Primary: MRI/MRA of Head/Neck/Chest. — 357 participants
Cancer
Primary: Maximum Observed Plasma Concentration and Concentration at Steady-state Following Multiple Doses of Vismodegib — 23.6; 30.7; 30.5; 20.5 micromolar
Renal Cell Carcinoma
Primary: Progression-free Survival — 1.7 months
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Lymphangioleiomyomatosis
Primary: Serum Vascular Endothelial Growth Factor-D (VEGF-D) Levels After Treatment With a Combination of Resveratrol and Sirolimus as Compared to Baseline Serum VEGF-D Levels on…
Carcinoma, Hepatocellular · Metastatic Colorectal Cancer
Primary: To Assess the Safety and Tolerability of Treatment With BTG-002814 — 8; 4 Participants
Carcinoma, Basal Cell
Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants
Malignant Melanoma
Primary: T 1/2 — 9.94 hr
Brain and Central Nervous System Tumors · Sarcoma
Primary: Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment. — 15 Participants
Vestibular Schwannoma · Neurofibromatosis Type 2
Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10
Carcinoma, Renal Cell
Primary: Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs) — 215; 31; 32; 16 Participants
Brain Tumor · Glioblastoma
Primary: Phase I: Determination of the Maximum Tolerated Dose (MTD) — 400 mg
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage III Renal Cell Cancer
Primary: Progression-free Survival Assessed by Response Evaluation Criteria for Solid Tumors (RECIST) (Phase II) — 48.6 percent
Adenocarcinoma of the Bladder · Distal Urethral Cancer · Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Primary: Tumor Response Rate — 4.5 percentage of responders
Tuberous Sclerosis Complex (TSC) · Lymphangioleiomyomatosis (LAM)
Primary: Angiomyolipoma Response Rate as Per Central Radiology Review — 41.8; 0; 58.0 Percentage of Participants — p=<0.0001
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
Malignant Adrenal Gland Pheochromocytoma · Malignant Paraganglioma · Metastatic Adrenal Gland Pheochromocytoma
Primary: Confirmed Tumor Response Rate — 1.0 participants
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Recurrent Renal Cell Carcinoma · Stage IV Renal Cell Cancer
Primary: Objective Response — 4; 7 participants